We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+27.77%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$8.73B
AUM Growth
+$1.49B
Cap. Flow
+$225M
Cap. Flow %
2.57%
Top 10 Hldgs %
31.85%
Holding
234
New
17
Increased
80
Reduced
68
Closed
12

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$143M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$63.9M
3
MRSN
Mersana Therapeutics
MRSN
+$42.8M
4
DXCM icon
DexCom
DXCM
+$32.7M
5
ABBV icon
AbbVie
ABBV
+$32.5M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$154M
2
HALO icon
Halozyme
HALO
+$51.2M
3
CRL icon
Charles River Laboratories
CRL
+$49.6M
4
CDNA icon
CareDx
CDNA
+$44.7M
5
MDT icon
Medtronic
MDT
+$40.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.9%
2 Technology 0.6%
3 Industrials 0.33%
4 Financials 0.11%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELV icon
26
Elevance Health
ELV
$83.4B
$108M 1.23%
335,793
-13,330
-4% -$4.09M
UNH icon
27
UnitedHealth
UNH
$385B
$107M 1.23%
306,045
-18,008
-6% -$6.04M
HUM icon
28
Humana
HUM
$48.1B
$97.3M 1.11%
237,067
-6,929
-3% -$2.88M
PODD icon
29
Insulet
PODD
$11.6B
$86.3M 0.99%
337,468
+67,593
+25% +$16.8M
CI icon
30
Cigna
CI
$75.1B
$86M 0.99%
413,208
+77,471
+23% +$15.2M
SYK icon
31
Stryker
SYK
$123B
$82.8M 0.95%
338,015
+15,244
+5% +$3.45M
BDX icon
32
Becton Dickinson
BDX
$42.9B
$82M 0.94%
335,950
+68,583
+26% +$16M
BSX icon
33
Boston Scientific
BSX
$65.7B
$79.4M 0.91%
2,209,859
+323,562
+17% +$11.7M
DXCM icon
34
DexCom
DXCM
$29.5B
$78.9M 0.9%
853,228
+366,408
+75% +$32.7M
EW icon
35
Edwards Lifesciences
EW
$49.2B
$75.4M 0.86%
826,918
-900
-0.1% -$74.7K
CNC icon
36
Centene
CNC
$32.9B
$71.1M 0.81%
1,185,047
+151,400
+15% +$9.62M
HOLX
37
DELISTED
Hologic
HOLX
$66.2M 0.76%
908,588
+211,608
+30% +$14.9M
GBIO
38
DELISTED
Generation Bio
GBIO
$66.1M 0.76%
233,318
+45,318
+24% +$14.5M
NKTR icon
39
Nektar Therapeutics
NKTR
$2.22B
$65.7M 0.75%
257,751
+15,594
+6% +$4.03M
JAZZ icon
40
Jazz Pharmaceuticals
JAZZ
$15.4B
$64.2M 0.74%
388,865
+32,515
+9% +$4.84M
HRC
41
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$63.9M 0.73%
652,525
+81,456
+14% +$7.61M
HCA icon
42
HCA Healthcare
HCA
$82.1B
$60.4M 0.69%
367,044
+21,959
+6% +$3.21M
ALGN icon
43
Align Technology
ALGN
$12.5B
$60.3M 0.69%
112,768
+28,133
+33% +$12.6M
MTEM
44
DELISTED
Molecular Templates, Inc.
MTEM
$60.2M 0.69%
427,489
+92,689
+28% +$13.7M
EXEL icon
45
Exelixis
EXEL
$14.1B
$59.1M 0.68%
2,944,500
-129,000
-4% -$2.7M
RLAY icon
46
Relay Therapeutics
RLAY
$4.22B
$58.6M 0.67%
1,409,357
+109,357
+8% +$4.94M
AXNX
47
DELISTED
Axonics, Inc. Common Stock
AXNX
$58.4M 0.67%
1,168,978
+524,034
+81% +$24.6M
INSP icon
48
Inspire Medical Systems
INSP
$1.51B
$56.3M 0.64%
299,217
+26,234
+10% +$4.29M
GWPH
49
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$54.5M 0.62%
472,389
-90,554
-16% -$10.1M
MDT icon
50
Medtronic
MDT
$107B
$54M 0.62%
461,258
-370,192
-45% -$40.8M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2020 Portfolio in Review

As of Q4 2020, Bellevue Group held 234 positions worth $8.73B, up 21% from $7.24B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Bellevue Group's Q4 2020 filing shows 17 new, 80 increased, 68 reduced and 12 closed positions. Its largest new stake was Mersana Therapeutics: 77,040 shares worth $51.3M. The largest sale was MyoKardia, Inc. Common Stock, an estimated $154M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Technology and Industrials.

  • Bellevue Group's largest Q4 2020 buy was Mersana Therapeutics: 77,040 shares worth $51.3M.
  • Bellevue Group added most to Biogen in Q4 2020, an estimated $143M increase.
  • Bellevue Group's biggest Q4 2020 reduction was Halozyme, cutting an estimated $51.2M.
  • Bellevue Group fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $154M.
  • Bellevue Group's ten largest holdings make up 32% of its $8.73B portfolio in Q4 2020.
  • Bellevue Group opened 17 new positions and closed 12 in Q4 2020.
  • Bellevue Group's portfolio value rose 21% quarter-over-quarter to $8.73B.

Based on Bellevue Group's 13F filing for Q4 2020, filed 16 Feb 2021.